# US 2016/0258953 A1 · Marker system, in particular for baculovirus-expressed subunit antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258953 A1
- Document ID: US20160258953A1
- Status: Published application
- Kind: A1
- Application number: 15/061,690
- Filed: 2016-03-04
- Published: 2016-09-08
- Earliest claimed: 2015-03-05
- Assignees: Boehringer Ingelheim Vetmedica GmbH
- Applicants: Boehringer Ingelheim Vetmedica, Inc.
- Inventors: Arun V. IYER; Joseph Ralph HERMANN; Michael B. ROOF; Eric Martin VAUGHN; Merrill Lynn SCHAEFFER
- Web page: https://patentgrep.com/patent/US20160258953A1

## CPC

- G01N 33/56983: {Viruses}
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12Q 1/701: {Specific hybridization probes}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/5252: {inactivated (killed)}
- C07K 2319/21: containing a His-tag
- C07K 2319/50: containing protease site
- C12N 2710/14021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/14022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/14043: viral genome or elements thereof as genetic vectore
- C12N 2710/14051: Methods of production or purification of viral material
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/10051: Methods of production or purification of viral material
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20051: Methods of production or purification of viral material
- G01N 2333/01: DNA viruses
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.

## Claims

### Claim 1

A method of determining whether an individual has received an immunogenic composition comprising: a recombinant protein produced by an expression system in cultured insect cells, wherein said method comprises determining in a biological sample obtained from said individual the presence or absence of one or more markers showing that the individual has received one or more antigens from a virus which is an RNA virus capable of infecting insect cells, and wherein the presence of said one or more markers in said biological sample indicates that said individual has received said immunogenic composition.

### Claim 2 (depends on 1)

The method of claim 1, wherein said expression system is a baculovirus expression system, and/or wherein said one or more markers showing that the individual has received one or more antigens from an RNA virus capable of infecting insect cells are one or more markers selected from the group consisting of:
a. antibodies specific for one or more antigens from a virus which is an RNA virus capable of infecting insect cells;
b. one or more antigens from a virus which is an RNA virus capable of infecting insect cells; and
c. one or more nucleic acid molecules specific for an RNA virus capable of infecting insect cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein said one or more antigens from an RNA virus capable of infecting insect cells is a protein comprising or consisting of:
a. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
b. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7.

### Claim 4 (depends on 2)

The method of claim 2, wherein said one or more nucleic acid molecules specific for an RNA virus capable of infecting insect cells is a nucleic acid molecule which encodes a protein comprising or consisting of:
a. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO: 1; and/or
b. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
c. said one or more nucleic acid molecules specific for an RNA virus capable of infecting insect cells is an RNA having a sequence that is inverse complementary to a nucleic acid sequence having at least at least 70% sequence identity with the sequence of SEQ ID NO:9; and/or
d. a sequence that is inverse complementary to a nucleic acid sequence having at least at least 70% sequence identity with the sequence of SEQ ID NO:15.

### Claim 5 (depends on 1)

The method of claim 1, comprising the steps of:
a. contacting the biological sample with a capture reagent immobilized to a solid support, wherein the immobilized capture reagent is capable of binding said one or more markers; and
b. determining the presence or absence of said one or more markers bound to the capture reagent, wherein the presence of said one or more markers bound to the capture reagent is indicative for the presence of said one or more markers in said biological sample.

### Claim 6 (depends on 5)

The method of claim 5, wherein said capture reagent is selected from the group consisting of:
a. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with a sequence selected from the group consisting of any one of SEQ ID NOs: 1 to 6;
b. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7 or SEQ ID NO:8;
c. an RNA virus capable of infecting insect cells, wherein said virus has optionally been inactivated and/or wherein said virus is optionally semipurified whole virus;
d. an oligonucleotide that is capable of specific hybridization with sequences characteristic of the sequence SEQ ID NO:9; and
e. an oligonucleotide that is capable of specific hybridization with sequences characteristic of the sequence SEQ ID NO:15.

### Claim 7 (depends on 1)

The method of claim 1, wherein said RNA virus is
a. a (−)ssRNA virus, preferably a virus which belongs to the family Rhabdoviridiae; and/or
b. said RNA virus capable of infecting insect cells is a virus which comprises:
i. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
ii. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
iii. said RNA virus capable of infecting insect cells is a virus whose genome comprises a nucleic acid molecule which encodes a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
iv. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
v. said RNA virus capable of infecting insect cells is a virus whose genome comprises an RNA molecule having a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:9;
vi. and/or a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:15.

### Claim 8 (depends on 1)

The method of claim 1, wherein said method comprises:
a. determining in said biological sample the presence or absence of said one or more markers, wherein said markers are antibodies specific for a protein comprising or consisting of:
i. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; or
ii. antibodies specific for a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and wherein said method comprises the steps of:
b. contacting the biological sample with a capture reagent immobilized to a solid support, wherein the capture reagent is selected from the group consisting of:
i. a protein comprising or consisting of a sequence having at least 70% sequence identity with a sequence selected from the group consisting of any one of SEQ ID NOs: 1 to 6, or a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7 or SEQ ID NO:8,
ii. an optionally inactivated virus which comprises a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1;
iii. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
iv. a virus whose genome comprises a nucleic acid molecule which encodes a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
v. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7, wherein said virus has optionally been inactivated,
vi. a virus whose genome comprises an RNA molecule which comprises a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:9; and/or
vii. a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:15, wherein said virus has optionally been inactivated; and/or
viii. a synthetic peptide having a sequence selected from the sequences consisting of 5 to 11 consecutive amino residues of SEQ ID NO:1 or SEQ ID NO:7; and
c. separating the biological sample from the immobilized capture reagent;
d. contacting the immobilized capture reagent-antibody complex with a detectable agent that binds to the antibody of the reagent-antibody complex; and
e. measuring the level of antibody bound to the capture reagent using a detection means for the detectable agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the measuring step (d) further comprises a comparison with a standard curve to determine the level of antibody bound to the capture reagent.

### Claim 10 (depends on 8)

The method of claim 8, wherein said detectable agent that binds to the antibody of the reagent-antibody complex is a detectable antibody, preferably a labelled secondary antibody.

### Claim 11 (depends on 5)

The method of claim 5, wherein said capture reagent is a baculovirus-expressed protein.

### Claim 12 (depends on 1)

The method of claim 1, further comprising the step of determining in said biological sample the presence of one or more analytes selected from the group consisting of antibodies specific for said recombinant protein, a polypeptide specific for said recombinant protein, a nucleotide sequence specific for the DNA sequence encoding said recombinant protein.

### Claim 13 (depends on 1)

The method of claim 1, wherein said recombinant protein is selected from the group consisting of PCV2 ORF2 protein, wherein said PCV2 ORF2 protein is preferably a protein having at least 90% sequence identity with the sequence of SEQ ID NO:23, and influenza hemagglutinin, preferably avian influenza hemagglutinin, in particular H5 protein of H5N1 virus, wherein said avian influenza hemagglutinin or H5 protein of H5N1 virus is preferably a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:24.

### Claim 14 (depends on 1, 20)

The method of claim 1, wherein said immunogenic composition is the composition of claim 20.

### Claim 15 (depends on 1)

The method of claim 1, wherein the biological sample has been isolated from a mammal or a bird, preferably from a pig or a chicken.

### Claim 16 (depends on 1)

The method of claim 1, wherein the biological sample is selected from the group consisting of whole blood, blood plasma, serum, urine, and oral fluids.

### Claim 17 (depends on 1)

The method of claim 1, wherein the immobilized capture reagent is coated on a microtiter plate.

### Claim 18

A recombinant baculovirus, wherein said baculovirus comprises a DNA sequence encoding a protein comprising or consisting of:
a. an amino acid sequence having at least 70% sequence identity with a sequence selected from the group consisting of:
i. SEQ ID NOs: 1 to 6; and/or
ii. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7 or SEQ ID NO:8; and/or
b. wherein said baculovirus comprises a DNA sequence comprising or consisting of:
i. a sequence having at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 9 to 14, and/or
ii. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:15 or SEQ ID NO:16.

### Claim 19

A vector, in particular a transfer vector, which contains a DNA sequence encoding a protein comprising or consisting of:
a. an amino acid sequence having at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 1 to: 6; and/or
b. a protein comprising or consisting of:
i. an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7 or SEQ ID NO:8; and/or
c. which contains a DNA sequence having at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 9 to 14; and/or a DNA sequence having at least 70% sequence identity with the sequence of SEQ ID NO: 15 or SEQ ID NO:16.

### Claim 20

An Immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells, and one or more antigens from a virus which is an RNA virus capable of infecting insect cells.

### Claim 21 (depends on 20)

The immunogenic composition of claim 20, wherein said RNA virus capable of infecting insect cells has been inactivated.

### Claim 22 (depends on 20)

The immunogenic composition of claim 20, wherein said recombinant protein is selected from the group consisting of:
a. a PCV2 ORF2 protein preferably comprising or consisting of a sequence having at least 90% sequence identity with the sequence of SEQ ID NO:23,
b. influenza hemagglutinin, preferably avian influenza hemagglutinin, in particular a H5 protein of H5N1 virus, wherein said avian influenza hemagglutinin or H5 protein of H5N1 virus is preferably a protein comprising or consisting of:
i. an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:24; and
ii. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 1 to 8.

### Claim 23 (depends on 20)

The immunogenic composition of claim 20, wherein said RNA virus comprises:
a. a (−)ssRNA virus, preferably a virus which belongs to the family Rhabdoviridiae; and/or said RNA virus capable of infecting insect cells is a virus which comprises a protein comprising or consisting of:
i. an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
ii. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
b. a RNA virus capable of infecting insect cells and whose genome comprises a nucleic acid molecule which encodes a protein comprising or consisting of:
i. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
ii. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
c. a RNA virus capable of infecting insect cells whose genome comprises:
i. an RNA molecule having a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:9; and/or
ii. a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:15.

### Claim 24 (depends on 20)

A method of producing the immunogenic composition of claim 20, comprising the steps of:
a. introducing a recombinant baculovirus encoding said recombinant protein into an insect cell, wherein said insect cell is infected with said RNA virus capable of infecting insect cells culturing said insect cell harboring said recombinant baculovirus and said RNA virus; and
b. recovering said recombinant protein and said virus, preferably in the supernate.

### Claim 25 (depends on 24)

The method of claim 24, further comprising the step of inserting a DNA sequence encoding said recombinant protein into a transfer vector capable of introducing said sequence into the genome of baculovirus, thereby producing recombinant baculovirus.

### Claim 26

A kit for determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells, wherein said kit contains one or more capture reagents immobilized to a solid support, wherein the one or more immobilized capture reagents are capable of binding of one or more markers selected from the group consisting of:
a. antibodies specific for one or more antigens from a virus which is an RNA virus capable of infecting insect cells;
b. one or more antigens from a virus which is an RNA virus capable of infecting insect cells; and
c. one or more nucleic acid molecules specific for an RNA virus capable of infecting insect cells.

### Claim 27 (depends on 26)

The kit of claim 26, wherein said one or more capture reagents are selected from the group consisting of:
a. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with a sequence selected from the group consisting of SEQ ID NOs: 1 to 6;
b. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7 or SEQ ID NO:8;
c. an RNA virus capable of infecting insect cells, wherein said virus has been inactivated, an oligonucleotide that is capable of specific hybridization with sequences characteristic of the sequence SEQ ID NO:9; and
d. an oligonucleotide that is capable of specific hybridization with sequences characteristic of the sequence SEQ ID NO:15.

### Claim 28 (depends on 26)

The kit of claim 26, wherein said RNA virus comprises or consists of:
a. a (−)ssRNA virus, preferably a virus which belongs to the family Rhabdoviridiae; and/or
b. a RNA virus capable of infecting insect cells which comprises a protein comprising or consisting of:
i. an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
ii. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
c. a RNA virus capable of infecting insect cells whose genome comprises a nucleic acid molecule which encodes a protein comprising or consisting of:
i. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
ii. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
d. a RNA virus capable of infecting insect cells whose genome comprises:
i. an RNA molecule having a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:9; and/or
ii. a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:15.

### Claim 29 (depends on 26)

The kit of claim 26, wherein said one or more antigens from an RNA virus capable of infecting insect cells is a protein comprising or consisting of:
a. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
b. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
c. one or more nucleic acid molecules specific for an RNA virus capable of infecting insect cells wherein said one or more nucleic acid molecules encode a protein comprising or consisting of:
i. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO: 1; and/or
ii. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
d. one or more nucleic acid molecules specific for an RNA virus capable of infecting insect cells wherein said one nucleic acid molecules is an RNA encoding a sequence comprising:
i. an inverse complement to a nucleic acid sequence having at least at least 70% sequence identity with the sequence of SEQ ID NO:3; and/or a
ii. an inverse complement to a nucleic acid sequence having at least at least 70% sequence identity with the sequence of SEQ ID NO:4.

### Claim 30 (depends on 1)

The method of claim 1, wherein said insect cell or insect cells are Spodoptera Frugiperda (Sf) cells or cells from a cell line derived from Spodoptera Frugiperda, preferably selected from the group consisting of Sf9 cells and Sf+ cells.

### Claim 31

A composition comprising a capture reagent,
wherein said capture reagent comprises or consists of viral particles and/or virus like particles of an RNA virus capable of infecting insect cells, and wherein said composition or said capture reagent is obtainable by a method comprising the steps of
i) obtaining supernatant from a culture of insect cells infected with an RNA virus capable of infecting insect cells, wherein said supernatant comprises viral particles and/or virus like particles of the RNA virus, and wherein said insect cells infected with an RNA virus capable of infecting insect cells are preferably not infected with a baculovirus and/or are preferably not transfected with a plasmid,
ii) separating cell debris from said viral particles and/or virus like particles via a separation step including a micro filtration through at least one filter, preferably two filters, wherein the at least one filter preferably having a pore size larger than said viral particles and/or virus like particles, in particular having a pore size of about 0.1 μm to about 4 μm, preferably of about 0.2 μm to about 2 μm,
iii) and optionally subjecting the filtrate of ii) which contains said viral particles and/or virus like particles to size exclusion chromatography, wherein the presence of protein in the eluent is measured by measuring the absorbance of light at 260 nm or 280 nm (A260 or A280), and wherein preferably the eluent exhibiting the first A260 or A280 peak is collected.

### Claim 32 (depends on 31)

The composition of claim 31, wherein said RNA virus comprises or consists of:
a. a (−)ssRNA virus, preferably a virus which belongs to the family Rhabdoviridiae; and/or
b. an RNA virus capable of infecting insect cells which comprises a protein comprising or consisting of:
i. an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
ii. a protein comprising or consisting of an amino acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
c. an RNA virus capable of infecting insect cells whose genome comprises a nucleic acid molecule which encodes a protein comprising or consisting of:
i. a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:1; and/or
ii. a protein comprising or consisting of a sequence having at least 70% sequence identity with the sequence of SEQ ID NO:7; and/or
d. an RNA virus capable of infecting insect cells whose genome comprises:
i. an RNA molecule having a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:9; and/or
ii. a sequence that is inverse complementary to a nucleic acid sequence having at least 70% sequence identity with the sequence of SEQ ID NO:15.
